M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: 3T Magnetic Resonance Spectroscopic Imaging

First Posted Date: 2007-04-24

Last Posted Date: 2020-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT00464724

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

Phase 2

Completed

Conditions: Renal Cell Cancer
Kidney Cancer

Interventions: Drug: Sunitinib Malate

First Posted Date: 2007-04-24

Last Posted Date: 2016-06-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00465179

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized Trial

Phase 3

Completed

Conditions: Brain Cancer

First Posted Date: 2007-04-16

Last Posted Date: 2012-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00460395

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Completed

Conditions: Myelodysplastic Syndrome
Acute Myelogenous Leukemia

Interventions: Behavioral: Questionnaire
Behavioral: Neurocognitive Testing

First Posted Date: 2007-04-12

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 104

Registration Number: NCT00459524

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Use of Spinal Sealant System During Spinal Surgery

Phase 3

Completed

Conditions: Spine Surgery
Excessive Repair
Spinal Cord Injuries
Complication of Surgical Procedure

Interventions: Device: Spinal Sealant
Procedure: Standard Methods of Closing of the Dura

First Posted Date: 2007-04-10

Last Posted Date: 2011-10-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00458354

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Evaluating Materials to Educate Patients About Cervical Dysplasia

Active, not recruiting

Conditions: Education
Cervical Dysplasia

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-04-02

Last Posted Date: 2020-12-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00454766

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

Completed

Conditions: Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Cervical Cancer

Interventions: Behavioral: Questionnaire
Behavioral: Patient Navigator (PN)

First Posted Date: 2007-03-29

Last Posted Date: 2020-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2472

Registration Number: NCT00453661

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Alemtuzumab and Pentostatin In T-cell Neoplasms

Phase 2

Terminated

Conditions: Lymphoma
Leukemia

Interventions: Drug: Pentostatin
Drug: Alemtuzumab

First Posted Date: 2007-03-28

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT00453193

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

A Study of Actonel for the Prevention of Bone Loss

Phase 3

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: Actonel (Risedronate)
Dietary Supplement: Calcium
Dietary Supplement: Vitamin D

First Posted Date: 2007-03-27

Last Posted Date: 2020-12-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 72

Registration Number: NCT00452439

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Cytarabine
Drug: Fludarabine
Drug: Oxaliplatin
Drug: Rituximab

First Posted Date: 2007-03-27

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00452374

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of California-San Diego, La Jolla, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy